Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Abivax SA Sponsored ADR ( (ABVX) ) has provided an announcement.
On December 15, 2025, Abivax SA announced its financial results for the third quarter of 2025, highlighting a significant increase in operating loss due to rising research and development expenses, particularly in its ulcerative colitis and Crohn’s disease programs. Despite a decrease in sales and marketing expenses, the company’s net loss widened due to increased personnel costs and financial losses related to convertible notes and warrants. Abivax’s cash position remains strong, with cash and cash equivalents of EUR 589.7 million, providing a runway into the fourth quarter of 2027.
The most recent analyst rating on (ABVX) stock is a Buy with a $142.00 price target. To see the full list of analyst forecasts on Abivax SA Sponsored ADR stock, see the ABVX Stock Forecast page.
Spark’s Take on ABVX Stock
According to Spark, TipRanks’ AI Analyst, ABVX is a Neutral.
The overall stock score is primarily influenced by strong technical momentum, which is offset by significant financial performance challenges and a weak valuation. The stock’s bullish trend is notable, but the financial instability and lack of earnings call or corporate events data limit the score.
To see Spark’s full report on ABVX stock, click here.
More about Abivax SA Sponsored ADR
Abivax SA is a clinical-stage biotechnology company based in Paris, France, focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
Average Trading Volume: 1,267,910
Technical Sentiment Signal: Buy
Current Market Cap: $9.9B
Find detailed analytics on ABVX stock on TipRanks’ Stock Analysis page.